Figure 4.

HQG treatment facilitates immunomodulation in lymphocytes: Prepared mice spleen lymphocytes from the tumour-bearing mice with (B) or without (A) HQG administration were fixed, stained with fluorescent-labelled CD4⁺ or CD8⁺ antibodies for 30 min followed by flow cytometry analysis to measure the percentage of CD4⁺ or CD8⁺ T-lymphocytes subpopulation. See detailed experimental protocol in Materials and Methods. UL means the percent of CD8⁺ cells, equal to the Th1 cells; LR means the percent of CD4⁺ cells, equal to the Th2 cells; LL means the CD4⁻ CD8⁻ cells; UR means the CD4⁺CD8⁺ cells. Prepared mice spleen lymphocytes from normal mice (C, a), tumour-bearing mice without (C, b, c) HQG or tumour-bearing mice with HQG administration (C, d, f) were fixed, stained and labelled antibodies against intracellular cytokines IL-4 and IFN-γ for 30 min followed by flow cytometry analysis to measure the percentage of cells secreting IL-4 (C, upper panel) or IFN-γ (C, lower panel). See detailed experimental protocol in Materials and Methods. UL: the percentage of IL-4⁺ cells; LR: the percentage of IFN-γ⁺ cells.